Investors

OvaScience is a global fertility company dedicated to improving treatment options for women around the world.

OVAS (Common Stock)
Price & Exchange
$7.88
NASDAQ
Change (%)
 Stock is Down 0.09 (1.13%)
Volume
282,170
09/28/16      12:39 p.m. ET

Minimum 20 minute delay
Refresh quote

Investor Overview

Recent News

More »
DateTitle 
09/14/16OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 14, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement awards to its newly appointed Chief Financial Officer, Christophe Couturier, and Executive Vice President, Regulatory, Clinical, Medical Affairs and Quality Assurance, Karen Long. The awards were approved by OvaScience’s Com... 
Printer Friendly Version
09/06/16OvaScience Announces Executive Management Changes and Appointments to Further Drive Company’s Growth
— Christophe Couturier Named Chief Financial Officer — — Karen Long Named Executive Vice President, Clinical and Regulatory Affairs and Quality Assurance — — James Luterman, Ph.D. Promoted to Executive Vice President, Research and Development — WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 6, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatmen... 
Printer Friendly Version
08/31/16OvaScience to Present at Upcoming Investor Conferences in September
WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 31, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Harald Stock, Ph.D., President and Chief Executive Officer, will present a corporate overview at three upcoming conferences:   ... 
Printer Friendly Version
08/29/16OvaScience’s AUGMENT Treatment Commercially Available in Japan Through Partnership with IVF JAPAN GROUP
— Japan Represents Large and Growing Infertility Market with More than 365,000 IVF Cycles Annually1 — WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 29, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that it has finalized its commercial agreement with the IVF JAPAN GROUP and that the AUGMENTSM treatment is now available to women ... 
Printer Friendly Version

Upcoming Events

More »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources